Health Care·Pharmaceuticals·$153.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.55 | N/A | -9.32% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.55 | N/A | -9.32% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management expressed caution regarding market conditions. They highlighted ongoing investments in research and development.
Management noted challenges in the competitive landscape.
They emphasized a focus on pipeline development moving forward.
Pfizer's earnings report showed a miss on EPS, which contributed to a 5.03% decline in stock price. The lack of revenue details and guidance may raise concerns among investors about the company's future performance. Management's cautious tone suggests they are aware of challenges ahead but remain focused on their product pipeline.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
GRACO INC
Jan 27, 2020